Previous 10 | Next 10 |
Gritstone Oncology (NASDAQ: GRTS ) has priced its public offering of 6.5M common shares at $11.50 per share, expected to yield gross proceeds of ~$74.8M. Underwriters over-allotment is an additional 975K shares. Closing date is April 29. More news on: Gritstone Oncology, Inc., Healthcare...
Gritstone Oncology (NASDAQ: GRTS ) has priced public offering of 6.5M shares of common stock at $11.50 per share, for estimated gross proceeds of ~$74.8M. More news on: Gritstone Oncology, Inc., Read more ...
EMERYVILLE, Calif., April 24, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq:GRTS) today announced the pricing of its underwritten public offering of 6,500,000 shares of common stock at a public offering price of $11.50 per share, before underwriting discounts and commissions. Al...
I recently had the pleasure of attending the 18th annual Bio-IT world Conference and Expo at the Seaport World Trade Center in Boston with more than 3,000 researchers, bioinformaticians, and experts. My reason for attending the conference was that, during my analysis of some biotechnology comp...
EMERYVILLE, Calif., April 22, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq:GRTS) today announced that it has commenced an underwritten public offering of 6,500,000 shares of common stock. All of the shares of common stock are being offered by Gritstone Oncology. In addition, Gr...
Novartis ( NVS ): The stock has been tumbling after the company announced interim data from the Phase 2 STR1VE trial of Zolgensma/AVXS-101 in spinal muscular atrophy ( SMA ) Type 1. While it's true that prolonged event-free survival and rapid increase in CHOP-INTEND scores were encouragi...
Gritstone Oncology (NASDAQ: GRTS ) announces that following feedback from the FDA, the SLATE Phase 1 clinical study may be accelerated by up to six months by leveraging pre-clinical data generated for the original GRANITE IND application. More news on: Gritstone Oncology, Inc., Healthcar...
Quick Take Hookipa Pharma ( HOOK ) has filed proposed terms to raise $100 million in a U.S. IPO, per an amended registration statement . Hookipa is advancing a pipeline of immunotherapeutics for infectious diseases and cancers. HOOK has generated promising trial results for its lead can...
EMERYVILLE, Calif., April 04, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Eugene Zhukovsky, Ph.D., an expert in the deve...
EMERYVILLE, Calif., April 03, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Andrew Allen, M.D., Ph.D., co-founder, president...
News, Short Squeeze, Breakout and More Instantly...
Gritstone Oncology Inc. Company Name:
GRTS Stock Symbol:
NASDAQ Market:
Gritstone Oncology Inc. Website:
-- Event will feature Dr. Randolph Hecht (Professor, UCLA GI Oncology Program) and Howard Brown (CRC Survivor, Patient and Advocate) -- EMERYVILLE, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the...
2024-06-14 13:15:03 ET JMP Securities analyst issues MARKET OUTPERFORM recommendation for GRTS on June 14, 2024 11:01AM ET. The previous analyst recommendation was Market Outperform. GRTS was trading at $0.7575 at issue of the analyst recommendation. The overall analyst ...
2024-05-24 11:30:04 ET B. Riley analyst issues BUY recommendation for GRTS on May 24, 2024 09:31AM ET. The previous analyst recommendation was Buy. GRTS was trading at $0.8039 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...